Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TROXYCA ER vs ADDERALL 20
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TROXYCA ER is a fixed-dose combination of oxycodone hydrochloride, a mu-opioid receptor agonist, and naltrexone hydrochloride, a mu-opioid receptor antagonist. Naltrexone is sequestered in the core of the tablet and is not released if taken as directed; however, if crushed or chewed, naltrexone is released and blocks the effects of oxycodone, reducing abuse potential.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy,Off-label: Treatment-resistant depression, obesity, cognitive enhancement
One capsule orally once daily at approximately the same time each day. The dosage strength should be individualized based on prior opioid use and tolerance. For opioid-naive patients, initiate with the lowest available strength (e.g., 60 mg/3.2 mg). Titrate no more frequently than every 3-7 days as needed.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
Tramadol: 5–6 hours; acetaminophen: 2–3 hours. Clinical context: Steady-state reached in ~1-2 days.
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
Oxycodone is extensively metabolized in the liver via CYP3A4 and CYP2D6; naltrexone is metabolized primarily to 6β-naltrexol by dihydrodiol dehydrogenase.
Primarily hepatic via CYP2D6 and, to a lesser extent, CYP2C19, CYP3A4, and CYP2C9. Metabolites include 4-hydroxyamphetamine, alpha-hydroxyamphetamine, and norephedrine.
Renal: ~70% as unchanged drug and metabolites (tramadol, acetaminophen), biliary/fecal: ~30%.
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Tramadol: ~20% bound primarily to albumin; acetaminophen: negligible binding (<5%).
16% (primarily albumin).
Tramadol: ~2.6–3.0 L/kg; acetaminophen: ~0.9–1.0 L/kg. Indicates extensive tissue distribution for tramadol.
3.2-5.6 L/kg; indicates extensive tissue distribution.
Oral: ~75% (tramadol); acetaminophen: ~88%.
Oral IR: ~90%; ER: ~90%.
For GFR 30-89 m L/min: No adjustment recommended. For GFR 15-29 m L/min: Initiate with 60 mg/3.2 mg once daily and titrate cautiously; monitor for respiratory depression. For GFR <15 m L/min: Not recommended due to accumulation of metabolites.
e GFR 15-29 m L/min: 50% of usual dose. e GFR < 15 m L/min: avoid use due to accumulation risk. Hemodialysis: not recommended.
For Child-Pugh Class A (mild impairment): No adjustment. For Child-Pugh Class B (moderate impairment): Initiate with 60 mg/3.2 mg once daily and titrate cautiously. For Child-Pugh Class C (severe impairment): Not recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use.
Not approved for use in pediatric patients (safety and efficacy not established).
Children 3-5 years: 2.5 mg orally once daily; increase by 2.5 mg weekly. Children 6 years and older: 5 mg once or twice daily; increase by 5 mg weekly. Maximum dose: 40 mg/day (immediate-release). Weight-based: 0.3-1.5 mg/kg/day (immediate-release).
Initiate with the lowest available strength (60 mg/3.2 mg) once daily and titrate cautiously due to increased sensitivity and risk of respiratory depression; consider renal function decline.
Initial: 2.5 mg once or twice daily; increase slowly by 2.5 mg increments at weekly intervals. Use lowest effective dose due to increased sensitivity and risk of cardiovascular adverse effects.
WARNING: ADDICTION, ABUSE AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Abuse and dependence: Amphetamines have a high potential for abuse, which can lead to dependence and serious cardiovascular events. Misuse may cause sudden death or serious cardiovascular adverse events.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Interaction with alcohol,Risk of severe hypotension,Risk of seizures in patients with seizure disorders,Avoid use in patients with gastrointestinal obstruction
Cardiovascular: Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Psychiatric: Exacerbation of pre-existing psychosis, mania, or aggression; new-onset psychosis or mania.,Growth suppression: Long-term use in children may suppress growth.,Seizures: May lower seizure threshold in patients with seizure disorders.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction (including paralytic ileus),Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of such therapy,Hypersensitivity to oxycodone, naltrexone, or any component of the product
Hypersensitivity to amphetamine or any component of the formulation,Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use or within 14 days of MAO inhibitors (risk of hypertensive crisis)
Avoid alcohol and alcoholic beverages. No specific food restrictions; however, a high-fat meal may slightly increase oxycodone absorption, but no dose adjustment needed.
High-fat meals can delay absorption of Adderall. Acidic foods (e.g., citrus fruits, juices) and vitamin C may decrease absorption; avoid within 1 hour of dosing. Caffeine and other stimulants may increase side effects. Alcohol should be avoided. Grapefruit juice may increase amphetamine levels, so limit or avoid.
First trimester: No adequate human data; animal studies show no teratogenicity at exposures up to 10 times MRHD. Second/third trimester: Prolonged use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid chronic use.
First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of fetal growth restriction, preterm birth, neonatal withdrawal syndrome (irritability, poor feeding), and persistent pulmonary hypertension. Chronic use may impair fetal development.
M/P ratio unknown. Oxycodone and naltrexone enter breast milk in low amounts; monitor infant for sedation and respiratory depression. Benefits may outweigh risks with short-term use.
Excreted into breast milk; M/P ratio approximately 2.5–7.5. Relative infant dose estimated at 5–14% of maternal weight-adjusted dose. Potential for decreased appetite, insomnia, and growth suppression in breastfed infants. American Academy of Pediatrics recommends use only if benefit outweighs risk, with close monitoring.
No specific dose adjustments recommended; pharmacokinetic changes (e.g., increased clearance, decreased protein binding) may necessitate careful titration. Use lowest effective dose for shortest duration.
Due to increased renal clearance and expanded plasma volume, total amphetamine exposure may decrease, potentially requiring dose increase (monitor clinical response). However, insufficient data to recommend fixed adjustments; individualize based on symptom control and tolerability.
TROXYCA ER is a fixed-dose combination of oxycodone and naltrexone designed for abuse deterrence. The naltrexone is sequestered and released only if the tablet is crushed, precipitating withdrawal in opioid-dependent individuals. It is not indicated for PRN use; only for around-the-clock management of severe chronic pain. Avoid in patients with opioid dependence due to risk of precipitated withdrawal. Do not administer with alcohol or other CNS depressants due to additive effects. Monitor for respiratory depression, especially in elderly or debilitated patients.
Adderall 20 mg is a mixed amphetamine salt formulation (75% dextroamphetamine, 25% levoamphetamine). Monitor for cardiovascular adverse effects; consider baseline ECG in patients with cardiac risk factors. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or arrhythmias. Use with caution in patients with hypertension, hyperthyroidism, or glaucoma. May exacerbate tics and Tourette syndrome. Administer first dose upon awakening; avoid afternoon doses due to insomnia risk. Monitor growth in children; may cause weight loss and growth suppression. Assess for potential for abuse and dependence; use lowest effective dose.
Take exactly as prescribed; do not crush, chew, or dissolve tablets.,This medication contains an opioid that can be habit-forming; use only for your pain and do not share with others.,Do not drink alcohol while taking this medication; it can increase the risk of severe drowsiness and respiratory depression.,Common side effects include constipation, nausea, dizziness, and drowsiness; report severe or persistent symptoms.,Store safely out of reach of children and dispose of unused tablets via a take-back program or flushing (per FDA guidelines).,Do not stop abruptly without talking to your doctor to avoid withdrawal symptoms.
Take exactly as prescribed; do not crush or chew extended-release capsules.,Take early in the morning to avoid trouble sleeping.,Avoid taking with high-fat meals as it may delay absorption.,Do not drink alcohol while taking this medication.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid driving or operating heavy machinery until you know how Adderall affects you.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.,Do not share your medication with others; it is a controlled substance.,Inform your doctor if you have a history of heart disease, high blood pressure, seizures, or mental health conditions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TROXYCA ER vs ADDERALL 20, answered by our medical review team.
TROXYCA ER is a Opioid Analgesic (with abuse-deterrent properties) that works by TROXYCA ER is a fixed-dose combination of oxycodone hydrochloride, a mu-opioid receptor agonist, and naltrexone hydrochloride, a mu-opioid receptor antagonist. Naltrexone is sequestered in the core of the tablet and is not released if taken as directed; however, if crushed or chewed, naltrexone is released and blocks the effects of oxycodone, reducing abuse potential.. ADDERALL 20 is a CNS Stimulant that works by Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TROXYCA ER and ADDERALL 20 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TROXYCA ER is: One capsule orally once daily at approximately the same time each day. The dosage strength should be individualized based on prior opioid use and tolerance. For opioid-naive patients, initiate with the lowest available strength (e.g., 60 mg/3.2 mg). Titrate no more frequently than every 3-7 days as needed.. The standard adult dose of ADDERALL 20 is: Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TROXYCA ER and ADDERALL 20 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TROXYCA ER is classified as Category C. First trimester: No adequate human data; animal studies show no teratogenicity at exposures up to 10 times MRHD. Second/third trimester: Prolonged use may cause neonatal opioid wit. ADDERALL 20 is classified as Category C. First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.